Hunger Stack

LGD

LGD-4033 is an orally-available, non-steroidal SARM that has delivered exceptional results in both preclinical and clinical trials, and it continues to be the subject of high-impact research. It is being investigated clinically and preclinically for a number of indications: increased muscle mass and strength; increased bone formation and strength; and central nervous system benefits including enhanced cognition and libido. Anabolicum (LGD-4033) is categorized as a SARM. LGD-4033 has the capability to bind to the AR (androgen receptor) with an extremely high affinity, in a manner that is tissue selective. It was originally developed to treat muscle wasting in cancer patients, age-related muscle loss as well as acute and chronic illness. LGD-4033 has been shown to produce similar therapeutic benefits to exogenous testosterone but with a better safety profile. This is due to it’s tissue-selective mechanism of action in conjunction with an administration taken orally. It also contains the ability to have anabolic activity in muscles, anti-resorptive and anabolic activity in bones as well as a selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has also been shown to promote tissue healing similar to Ostabolic (MK-2866) and Nutrobal (MK-677).

MK-677

Ghrelin is an endogenous ligand for the growth hormone (GH) secretagogue receptor (GHSR). Ibutamoren (MK-677) is an orally-active, non-peptidic agonist of GHSR and, as a result, is a GH secretagogue. It elevates GH in dogs after oral doses as low as 0.125 mg/kg, without significantly changing plasma levels of aldosterone, luteinizing hormone, thyroxine, or prolactin.